Last reviewed · How we verify

Retinal Consultants of Arizona — Portfolio Competitive Intelligence Brief

Retinal Consultants of Arizona pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lucentis (Treat and extend) Lucentis (Treat and extend) marketed VEGF inhibitor (monoclonal antibody fragment) VEGF-A Ophthalmology
Lucentis every 4 weeks Lucentis every 4 weeks marketed VEGF-A inhibitor (monoclonal antibody fragment) VEGF-A Ophthalmology
Lucentis every 12 weeks Lucentis every 12 weeks marketed VEGF-A inhibitor (monoclonal antibody fragment) VEGF-A Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Greater Houston Retina Research · 1 shared drug class
  4. Hoffmann-La Roche · 1 shared drug class
  5. Hospital Regional de São José - Dr. Homero de Miranda Gomes · 1 shared drug class
  6. Jaeb Center for Health Research · 1 shared drug class
  7. LEANDRO CABRAL ZACHARIAS · 1 shared drug class
  8. Medical University of Vienna · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Retinal Consultants of Arizona:

Cite this brief

Drug Landscape (2026). Retinal Consultants of Arizona — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/retinal-consultants-of-arizona. Accessed 2026-05-17.

Related